Vedanta Biosciences sharply reduced headcount and furloughed staff to concentrate remaining resources on its lead live‑biotherapeutic candidate VE303 and its Phase 3 program for recurrent Clostridioides difficile infection. The company said the restructuring was intended to preserve progress on a program it positions as supported by strong Phase 2 data; reports indicate roughly half the workforce was cut or furloughed. Vedanta’s move echoes industry pressure on microbiome players after recent late‑stage setbacks and highlights financing risk for platform companies seeking to reach registrational milestones.